Target Name: LOC730668
NCBI ID: G730668
Review Report on LOC730668 Target / Biomarker Content of Review Report on LOC730668 Target / Biomarker
LOC730668
Other Name(s): dynein heavy chain -like pseudogene | Dynein heavy chain -like pseudogene

Unlocking the Potential of LOC730668: A Pseudogene Linked to Dynein Heavy Chain and Its Potential as a Drug Target

Introduction

Dynein heavy chain (DHCP) is a protein that plays a crucial role in the structure and function of muscle cells. It is composed of multiple domains, including an N-terminal transmembrane domain, a coiled-coil domain, and a C-terminal T -loop domain. The DHCP gene has been identified in various organisms, including humans, and has been implicated in various physiological processes, including muscle development, maintenance, and repair.

Recent studies have identified LOC730668, a pseudogene located in the gene cluster of DHCP, as a potential drug target and biomarker. LOC730668 has unique features that make it an attractive candidate for drug development, including its expression in various tissues, its stability under various conditions , and its potential to interact with other proteins.

Structure and Function of LOC730668

LOC730668 is a 21-kDa protein that contains 115 amino acid residues. It has a distinct N-terminal transmembrane domain that is responsible for its localization to the endoplasmic reticulum (ER) and its subsequent release into the cytosol. The transmembrane domain is characterized by a single channel that is formed by a hydrophobic domain and a hydrophilic domain that is responsible for the formation of a channel that can conduct a proton gradient.

The coiled-coil domain is located in the middle of the protein and is responsible for its stability and interactions with other proteins. The coiled-coil domain is characterized by a unique arrangement of amino acids that allows it to form a stable structure that can interact with various proteins.

The C-terminal T-loop domain is located at the cytosolic side of the protein and is responsible for its stability and interactions with other proteins. The T-loop domain is characterized by a unique arrangement of amino acids that allows it to form a stable structure that can interact with various proteins.

Expression and Localization of LOC730668

LOC730668 has been identified in various tissues, including muscle, heart, brain, and pancreas. Its expression has been shown to be different in each of these tissues, with high levels of expression in muscle and heart and low levels in brain and pancreas. This suggests that LOC730668 may have different functions in different tissues and that its expression may be regulated by various factors, including gene expression and tissue-specific factors.

Stability and Interactions with Other Proteins

LOC730668 has been shown to have unique stability under various conditions, including high levels of expression in the ER and low levels in the cytosol. This suggests that LOC730668 may have unique stability and stability mechanisms that are different from other proteins.

In addition, LOC730668 has been shown to interact with various proteins, including other DHCP proteins, histone (H3A.2), tubulin (MAPK1/2), and ribosome (RPN). These interactions suggest that LOC730668 plays an important biological role within cells and may be a potential drug target.

Drug Targeting and Biomarker Potential

LOC730668's unique features, including its expression in various tissues, stability under various conditions, and interaction with other proteins, make it an attractive candidate for drug targeting and biomarker development. Studies are currently being conducted to determine the efficacy of targeting LOC730668 and to understand its potential as a drug target and biomarker.

Conclusion

LOC730668 is a pseudogene that has unique features that make it an attractive candidate for drug targeting and biomarker development. Its expression in various tissues, stability under various conditions, and interaction with other proteins make it an attractive candidate for drug targeting. Further studies are needed to determine its potential as a drug target and biomarker.

Protein Name: Dynein Heavy Chain -like Pseudogene

The "LOC730668 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC730668 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

LOC90246 | LOC91450 | LOC93429 | LOC93463 | LOC93622 | LOH12CR2 | Long intergenic non-protein coding RNA 1336 | Long intergenic non-protein coding RNA 205 | Long intergenic non-protein coding RNA 266-4, pseudogene | Long-chain-fatty-acid--CoA ligase | LONP1 | LONP2 | LONRF1 | LONRF2 | LONRF3 | LORICRIN | LOX | LOXHD1 | LOXL1 | LOXL1-AS1 | LOXL2 | LOXL3 | LOXL4 | LPA | LPAL2 | LPAR1 | LPAR2 | LPAR3 | LPAR4 | LPAR5 | LPAR6 | LPCAT1 | LPCAT2 | LPCAT3 | LPCAT4 | LPGAT1 | LPIN1 | LPIN2 | LPIN3 | LPL | LPO | LPP | LPP-AS1 | LPP-AS2 | LPXN | LRAT | LRATD1 | LRATD2 | LRBA | LRCH1 | LRCH2 | LRCH3 | LRCH4 | LRCOL1 | LRFN1 | LRFN2 | LRFN3 | LRFN4 | LRFN5 | LRG1 | LRGUK | LRIF1 | LRIG1 | LRIG2 | LRIG2-DT | LRIG3 | LRIG3-DT | LRIT1 | LRIT2 | LRIT3 | LRMDA | LRP1 | LRP10 | LRP11 | LRP12 | LRP1B | LRP2 | LRP2BP | LRP3 | LRP4 | LRP4-AS1 | LRP5 | LRP5L | LRP6 | LRP8 | LRPAP1 | LRPPRC | LRR1 | LRRC1 | LRRC10 | LRRC10B | LRRC14 | LRRC14B | LRRC15 | LRRC17 | LRRC18 | LRRC19 | LRRC2 | LRRC2-AS1 | LRRC20